



Figure S3. TiME at Baseline and After Treatment.

(A) Percentages of total CD45 cells that were CD8⁺, (B) percentages of total CD45⁺ cells that were granulocytes, (C) ratios of CD163⁻ to CD163⁺CD68⁺ monocytes/macrophages, and (D) percentages of total CD4⁺ T cells that were positive for ICOS are shown for each patient at baseline and after 43 days of treatment. Pembrolizumab monotherapy, n=5; pembrolizumab plus acalabrutinib combination therapy, n=3 at baseline and n=2 at day 43. Green lines joining baseline and treatment paired samples reflect a >10% increase after treatment compared with baseline, red lines indicate a >10% decrease after treatment compared with baseline, and the black line (Panel B, right) indicates a change of <10% after treatment compared with baseline. ICOS, inducible co-stimulator; TiME, tumor-immune microenvironment.


A



B



C



D

